Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms

References

• Valent P, Ashman LK, Hinterberger W, et al. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 1989;73:1778–1785.
   PubMed Web of Science ®Google Scholar
• Horny HP, Schaumburg-Lever G, Bolz S, Geerts ML, Kaiserling E. Use of monoclonal antibody KP1 for identifying normal and neoplastic human mast cells. J Clin Pathol 1990;43:719–722.
   PubMed Web of Science ®Google Scholar
• Valent P, Majdic O, Maurer D, Bodger M, Muhm M, Bettelheim P. Further characterization of surface membrane structures expressed on human basophils and mast cells. Int Arch Allergy Appl Immunol 1990;91:198–203.
   PubMedGoogle Scholar
• Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol 1992;52:333–423.
   PubMed Web of Science ®Google Scholar
• Horny HP, Ruck P, Xiao JC, Kaiserling E. Immunoreactivity of normal and neoplastic human tissue mast cells with macrophage-associated antibodies, with special reference to the recently developed monoclonal antibody PG-M1. Hum Pathol 1993;24:355–358.
   PubMed Web of Science ®Google Scholar
• Agis H, Füreder W, Bankl HC, et al. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology 1996;87:535–543.
   PubMed Web of Science ®Google Scholar
• Ghannadan M, Baghestanian M, Wimazal F, et al. Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. J Invest Dermatol 1998;111:689–695.
   PubMed Web of Science ®Google Scholar
• Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology 1979;3:349–365.
   PubMed Web of Science ®Google Scholar
• Parwaresch MR, Horny HP, Lennert K. Tissue mast cells in health and disease. Pathol Res Pract 1985;179:439–461.
   PubMed Web of Science ®Google Scholar
• Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991;96:2S–4S.
   Web of Science ®Google Scholar
• Valent P. Biology, classification and treatment of human mastocytosis. Wiener Klin Wochenschr 1996;108:385–397.
   PubMed Web of Science ®Google Scholar
• Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603–625.
   PubMed Web of Science ®Google Scholar
• Valent P, Horny H-P, Li CY, et al. Mastocytosis (mast cell disease). World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissuesIn: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Lyon: IARC Press, 2001. pp 291–302.
   Google Scholar
• Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis (mast cell disease). World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissuesIn: Swerdlow SH, Campo E, Harris NL, et al, editors. Lyon: IARC Press, 2008. pp 54–63.
   Google Scholar
• Sperr WR, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001;25:529–536.
   PubMed Web of Science ®Google Scholar
• Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560–10564.
   PubMed Web of Science ®Google Scholar
• Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312–314.
   PubMed Web of Science ®Google Scholar
• Escribano L, Orfao A, Díaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998;91:2731–2716.
   PubMed Web of Science ®Google Scholar
• Valent P, Escribano L, Parwaresch RM, et al. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. Int Arch Allergy Immunol 1999;120:1–7.
   PubMed Web of Science ®Google Scholar
• Valent P, Schernthaner GH, Sperr WR, et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 2001;179:74–81.
   PubMed Web of Science ®Google Scholar
• Escribano L, Díaz-Agustín B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 2001;25:563–570.
   PubMed Web of Science ®Google Scholar
• Valent P, Sperr WR, Samorapoompichit P, et al. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. Leuk Res 2001;25:595–602.
   PubMed Web of Science ®Google Scholar
• Valent P, Samorapoompichit P, Sperr WR, Horny HP, Lechner K. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J 2002;3:90–94.
   PubMedGoogle Scholar
• Arredondo AR, Gotlib J, Shier L, et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol 2010;85:600–606.
   PubMed Web of Science ®Google Scholar
• Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-xL. Hum Pathol 2001;32:545–552.
   PubMed Web of Science ®Google Scholar
• Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319–1325.
   PubMed Web of Science ®Google Scholar
• Krokowski M, Sotlar K, Krauth MT, Födinger M, Valent P, Horny HP. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am J Clin Pathol 2005;124:560–568.
   PubMed Web of Science ®Google Scholar
• Baumgartner C, Sonneck K, Krauth MT, et al. Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry. Eur J Clin Invest 2008;38:326–335.
   PubMed Web of Science ®Google Scholar
• Escribano L, Orfao A, Villarrubia J, et al. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry 1997;30:98–102.
   PubMedGoogle Scholar
• Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol 2003;27:1013–1019.
   PubMed Web of Science ®Google Scholar
• Teodosio C, García-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010;125:719–726.
   PubMed Web of Science ®Google Scholar
• Schernthaner GH, Jordan JH, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood 2001;98:3784–3792.
   PubMed Web of Science ®Google Scholar
• Valent P, Cerny-Reiterer S, Herrmann H, et al. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol 2010;23:369–378.
   PubMed Web of Science ®Google Scholar
• Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001;25:543–551.
   PubMed Web of Science ®Google Scholar
• Stockinger H, Valent P, Majdic O, Bettelheim P, Knapp W. Human blood basophils synthesize interleukin-2 binding sites. Blood 1990;75:1820–1826.
   PubMed Web of Science ®Google Scholar
• Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848–858.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Podda A, Prolla G, et al. CD30 in normal and neoplastic cells. Clin Immunol 1999;90:157–164.
   PubMed Web of Science ®Google Scholar
• Sotlar K, Cerny-Reiterer S, Petat-Dutter K, et al. Aberrant expression of CD30 in neoplastic mast cells in high grade mastocytosis. Mod Pathol 2011; in press.
   PubMed Web of Science ®Google Scholar
• Horny HP, Sotlar K, Valent P. Differential diagnosis of systemic mastocytosis in routinely processed bone marrow biopsy speciments. Pathobiology 2010;77:169–180.
   PubMed Web of Science ®Google Scholar
• Merz H, Kähler C, Höfig K, et al. Interleukin-9 (IL-9) and NPM–ALK each generate mast cell hyperplasia as single ‘hit’ and cooperate with each other in producing a mastocytosis-like disease in mice. Oncotarget 2010;1:104–119.
   PubMedGoogle Scholar
• Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993;73:1349–1360.
   PubMed Web of Science ®Google Scholar
• Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 1994;6:407–413.
   PubMed Web of Science ®Google Scholar
• Gattei V, Degan M, Gloghini A, et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997;89:2048–2059.
   PubMed Web of Science ®Google Scholar
• Molin D, Fischer M, Xiang Z, et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 2001;114:616–623.
   PubMed Web of Science ®Google Scholar
• Fischer M, Harvima IT, Carvalho RF, et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 2006;116:2748–2756.
   PubMed Web of Science ®Google Scholar
• Hsu PL, Hsu SM. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma. Lab Invest 2000;80:1111–1119.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007;67:333–350.
   PubMed Web of Science ®Google Scholar
• Hirsch B, Brauer J, Fischdick M, et al. Anti-CD30 human IL-2 fusion proteins display strong and specific cytotoxicity in vivo. Curr Drug Targets 2009;10:110–117.
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812–1821.
   PubMed Web of Science ®Google Scholar